{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:16:34Z","timestamp":1783163794775,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40261-026-01551-1","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:11:54Z","timestamp":1778760714000},"page":"759-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetic Drug Interaction Studies of Limnetrelvir with Midazolam and Itraconazole in Healthy Participants"],"prefix":"10.1007","volume":"46","clinical-trial-number":[{"clinical-trial-number":"nct05691699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05895266","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8673-1327","authenticated-orcid":false,"given":"Janki M.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-3501","authenticated-orcid":false,"given":"Ekram Ahmed","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izna","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6841-2747","authenticated-orcid":false,"given":"Christine M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Orejudos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarna L.","family":"Yadlapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9261-1583","authenticated-orcid":false,"given":"Ahmed Hamed","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3065-768X","authenticated-orcid":false,"given":"Nael M.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"1551_CR1","unstructured":"WHO. Coronavirus disease (COVID-19) pandemic. Available at: https:\/\/www.who.int\/europe\/emergencies\/situations\/covid-19. Accessed 4 Feb 2025."},{"key":"1551_CR2","unstructured":"WHO. Number of COVID-19 deaths reported to WHO (cumulative total). https:\/\/data.who.int\/dashboards\/covid19\/deaths. Accessed 4 Feb 2025."},{"key":"1551_CR3","unstructured":"CDC. COVID-19 and how it spreads. Available at: https:\/\/www.cdc.gov\/covid\/about\/index.html. Accessed 4 Feb 2025."},{"key":"1551_CR4","unstructured":"WHO. Tracking SARS-CoV-2 variants. Available at: https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants. Accessed 4 Feb 2025."},{"key":"1551_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/emph\/eoac010","volume":"10","author":"M Amicone","year":"2022","unstructured":"Amicone M, Borges V, Alves MJ, Isidro J, Z\u00e9-Z\u00e9 L, Duarte S, et al. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol Med Public Health. 2022;10:142\u201355. https:\/\/doi.org\/10.1093\/emph\/eoac010.","journal-title":"Evol Med Public Health"},{"key":"1551_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1042\/bst20221037","volume":"51","author":"H-D Hoang","year":"2023","unstructured":"Hoang H-D, Naeli P, Alain T, Jafarnejad SM. Mechanisms of impairment of interferon production by SARS-CoV-2. Biochem Soc Trans. 2023;51:1047\u201356. https:\/\/doi.org\/10.1042\/bst20221037.","journal-title":"Biochem Soc Trans"},{"key":"1551_CR7","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang H, Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat Rev Microbiol. 2021;19:685\u2013700. https:\/\/doi.org\/10.1038\/s41579-021-00630-8.","journal-title":"Nat Rev Microbiol"},{"key":"1551_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biom14070797","author":"A Zag\u00f3rska","year":"2024","unstructured":"Zag\u00f3rska A, Czopek A, Fryc M, Jo\u0144czyk J. Inhibitors of SARS-CoV-2 main protease (Mpro) as anti-coronavirus agents. Biomolecules. 2024. https:\/\/doi.org\/10.3390\/biom14070797.","journal-title":"Biomolecules"},{"key":"1551_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02607-4","volume":"21","author":"S Gevorgyan","year":"2024","unstructured":"Gevorgyan S, Khachatryan H, Shavina A, Gharaghani S, Zakaryan H. Targeting SARS-CoV-2 main protease: a comprehensive approach using advanced virtual screening, molecular dynamics, and in vitro validation. Virol J. 2024;21:330. https:\/\/doi.org\/10.1186\/s12985-024-02607-4.","journal-title":"Virol J"},{"key":"1551_CR10","doi-asserted-by":"publisher","first-page":"34196","DOI":"10.1021\/acsomega.4c03023","volume":"9","author":"Y Yang","year":"2024","unstructured":"Yang Y, Luo Y-D, Zhang C-B, Xiang Y, Bai X-Y, Zhang D, et al. Progress in research on inhibitors targeting SARS-CoV-2 main protease (Mpro). ACS Omega. 2024;9:34196\u2013219. https:\/\/doi.org\/10.1021\/acsomega.4c03023.","journal-title":"ACS Omega"},{"key":"1551_CR11","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed 17 May 2025."},{"key":"1551_CR12","unstructured":"PAXLOVID\u2122 (nirmatrelvir tablets; ritonavir tablets) [package insert]. New York, NY, USA. Pfizer Labs. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217188s010lbl.pdf. Revised February 2025. Accessed 17 May 2025."},{"key":"1551_CR13","unstructured":"US Food and Drug Administration. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table2-1. Accessed 4 Feb 2025."},{"key":"1551_CR14","unstructured":"US Food and Drug Administration. FDA\u2019s examples of drugs that interact with CYP enzymes and transporter systems. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems#table%201. Accessed 4 Feb 2025."},{"key":"1551_CR15","unstructured":"AbbVie Inc. A Study to Assess Drug-Drug Interaction Between ABBV-903 and midazolam in adult healthy volunteers. ClinicalTrials.gov identifier: NCT05895266. Updated 09 November 2023. Accessed 4 Feb 2025"},{"key":"1551_CR16","unstructured":"AbbVie Inc. A study to assess adverse events and how single and multiple ascending doses of ABBV-903 move through the body in healthy adults. ClinicalTrials.gov identifier: NCT05691699. Updated 30 October 2023. Accessed 17 May 2025"},{"key":"1551_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10928-020-09704-1","volume":"47","author":"ST Wiebe","year":"2020","unstructured":"Wiebe ST, Meid AD, Mikus G. Composite midazolam and 1\u2032-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity. J Pharmacokinet Pharmacodyn. 2020;47:527\u201342. https:\/\/doi.org\/10.1007\/s10928-020-09704-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1551_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/jcph.2140","volume":"63","author":"D Mukherjee","year":"2023","unstructured":"Mukherjee D, Brackman DJ, Suleiman AA, Zha J, Menon RM, Salem AH. Impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics: a PBPK and population PK-informed analysis. J Clin Pharmacol. 2023;63:119\u201325. https:\/\/doi.org\/10.1002\/jcph.2140.","journal-title":"J Clin Pharmacol"},{"key":"1551_CR19","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2012. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 17 May 2025."},{"issue":"9","key":"1551_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/jcph.2447","volume":"64","author":"M Magliocca","year":"2024","unstructured":"Magliocca M, Berger B, Lemoine V, Kaufmann P, Dingemanse J. Value of assessing 1-hydroxymidazolam in drug-drug interaction studies with midazolam as a substrate of cytochrome P450 3A. J Clin Pharmacol. 2024;64(9):1123\u20139. https:\/\/doi.org\/10.1002\/jcph.2447. (Epub 2024 May 26).","journal-title":"J Clin Pharmacol"},{"key":"1551_CR21","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-limits-usage-nizoral-ketoconazole-oral-tablets-due-potentially. Accessed 4 Feb 2025."},{"key":"1551_CR22","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. 2012. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547869\/. Accessed 4 Feb 2025."},{"key":"1551_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/clpt.2014.41","volume":"95","author":"AB Ke","year":"2014","unstructured":"Ke AB, Zamek-Gliszczynski MJ, Higgins JW, Hall SD. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. Clin Pharmacol Ther. 2014;95:473\u20136. https:\/\/doi.org\/10.1038\/clpt.2014.41.","journal-title":"Clin Pharmacol Ther"},{"key":"1551_CR24","unstructured":"US Food and Drug Administration. M12 Drug Interaction Studies. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/m12-drug-interaction-studies. Accessed 4 Feb 2025."},{"key":"1551_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/psp4.12449","volume":"8","author":"Y Chen","year":"2019","unstructured":"Chen Y, Cabalu TD, Callegari E, Einolf H, Liu L, Parrott N, et al. Recommendations for the design of clinical drug\u2013drug interaction studies with Itraconazole using a mechanistic physiologically\u2010based pharmacokinetic model. CPT Pharmacomet Syst Pharmacol. 2019;8:685\u201395. https:\/\/doi.org\/10.1002\/psp4.12449.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1551_CR26","doi-asserted-by":"crossref","unstructured":"Chowdhury EA, Lee CM, Desai JM, Ali I, Orejudos A, Gupta SV, et al. Pharmacokinetic profiling of limnetrelvir in non-Japanese and Japanese populations: results of two phase 1 single- and multiple-dose studies. Accepted January 16, 2026 at Antimicrob Agents Chemother.","DOI":"10.1128\/aac.01443-25"},{"key":"1551_CR27","unstructured":"Center for Drug Evaluation and Research. NDA 217188 (Paxlovid [nirmatrelvir and ritonavir]). 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217188Orig1s000IntegratedR.pdf. Accessed 17 May 2025."},{"key":"1551_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70395","volume":"18","author":"J Chang","year":"2025","unstructured":"Chang J, Kim A, Humeniuk R, Shaik NA, Winter H, Peng C, et al. Characterization of drug\u2013drug interactions for remdesivir, an intravenous antiviral for SARS\u2010CoV\u20102, in healthy participants. Clin Transl Sci. 2025;18:e70395. https:\/\/doi.org\/10.1111\/cts.70395.","journal-title":"Clin Transl Sci"},{"key":"1551_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cmi.2024.09.007","volume":"31","author":"P-P Ye","year":"2025","unstructured":"Ye P-P, Yao B-F, Yang Y, Yang X-M, Li Q, Song L-L, et al. Drug-drug interactions of simnotrelvir\/ritonavir: an open-label, fixed-sequence, two-period clinical trial. Clin Microbiol Infect. 2025;31:101\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2024.09.007.","journal-title":"Clin Microbiol Infect"},{"key":"1551_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1208\/s12248-020-00469-6","volume":"22","author":"JK Sodhi","year":"2020","unstructured":"Sodhi JK, Benet LZ. The necessity of using changes in absorption time to implicate intestinal transporter involvement in oral drug-drug interactions. AAPS J. 2020;22:111\u2013111. https:\/\/doi.org\/10.1208\/s12248-020-00469-6.","journal-title":"AAPS J"},{"key":"1551_CR31","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11095-021-03039-3","volume":"38","author":"W Kou","year":"2021","unstructured":"Kou W, Sodhi JK, Wu X, Benet LZ. Investigating intestinal transporter involvement in Rivaroxaban disposition through examination of changes in absorption. Pharm Res. 2021;38:795\u2013801. https:\/\/doi.org\/10.1007\/s11095-021-03039-3.","journal-title":"Pharm Res"},{"key":"1551_CR32","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.3390\/pharmaceutics14112493","volume":"14","author":"D Malno\u00eb","year":"2022","unstructured":"Malno\u00eb D, Fardel O, Corre PL. Involvement of transporters in intestinal drug\u2013drug interactions of oral targeted anticancer drugs assessed by changes in drug absorption time. Pharmaceutics. 2022;14:2493\u20132493. https:\/\/doi.org\/10.3390\/pharmaceutics14112493.","journal-title":"Pharmaceutics"},{"key":"1551_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13318-020-00668-8","volume":"46","author":"S Deb","year":"2021","unstructured":"Deb S, Arrighi S. Potential effects of COVID-19 on Cytochrome P450-mediated drug metabolism and disposition in infected patients. Eur J Drug Metab Pharmacokinet. 2021;46:185\u2013203. https:\/\/doi.org\/10.1007\/s13318-020-00668-8.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1551_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/17425255.2023.2228680","volume":"19","author":"S Villemure","year":"2023","unstructured":"Villemure S, Trenaman SC, Goralski KB. The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions. Expert Opin Drug Metab Toxicol. 2023;19:329\u201332. https:\/\/doi.org\/10.1080\/17425255.2023.2228680.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01551-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01551-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01551-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:29:44Z","timestamp":1783160984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01551-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1551"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01551-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Janki M. Desai, Ekram Ahmed Chowdhury, Christine M. Lee, Jeffrey M. Schmidt, Amelia Orejudo, Swarna L. Yadlapalli, Shelly Gupta, Christopher Ocampo, Michael G. Miller, and Nael M. Mostafa are employees of AbbVie and may hold stock, stock options, or patents with the company. Izna Ali\u00a0and Ahmed Hamed Salem are former AbbVie employees and may hold AbbVie stock or options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The studies reported herein were conducted in accordance with the International Council for Harmonisation (ICH) guidelines, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. Approval was granted by Advarra IRB (Columbia, MO, USA; NCT05895266, IRB Protocol number: Pro00071632, date: May 2023; NCT05691699, IRB Protocol number: Pro00068284, date: September 2023) for both studies reported herein.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants provided written consent prior to participation or study-related procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All individual participants signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:\n                      \n                      then select \u201cHome\u201d.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"I.A., E.A.C., C.M.L., C.J.O., M.G.M, and N.M.M. designed the research. All authors performed the research. J.M.D. drafted the original manuscript. All authors critically reviewed and approved the final version and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution statements"}}]}}